Preventing congestion in acute heart failure patients

German Adrenomed AG has decided to start clinical Phase II tests of the very first personalised treatment for the six million patients with acute congestive heart failure. Large trials suggest that the company can stratify patients resistant to diuretics standard therapy by a proprietary companion diagnostics blood test. Adrenomed will assess whether its first-in-class antibody adrecizumab can reverse the congestion that that manifests as pulmonary edema.
Read more

Abivax’ shares jump on new Phase IIa HIV data

The French biotech said that its lead therapeutic candidate demonstrated the first reduction in HIV reservoirs ever observed in chronically infected HIV patients. Following the news, the company’s share price more than doubled.

Read more

Verona Pharma raised US-$77.8m at NASDAQ

British respiratory disease specialist Verona Pharma plc (VRNA) has raised US-$77.8m (€73,96m) at NASDAQ through the issuance of 5,768,000 American Depositary Shares (ADS) – each ADS representing eight ordinary shares – at a price of US-$13.50 per ADS.

Read more

Modus Therapeutics: Clinical development pro

Modus Therapeutics AB, a Karolinska Development portfolio company developing treatments for sickle cell disease, has appointed Ellen K. Donnelly as CEO. Donnelly joins from Pfizer, Inc, where she most recently was responsible for Clinical Operations for the Neuroscience and Pain therapeutic area.

Read more

EuropaBio: Regulatory experience

The European biotech industry association EuropaBio has named John Brennan as its new Secretary General. The life sciences expert will take over his new position in June. 
Read more

Epigenomics in €171m take-over

Epigenomics and minority shareholder Cathay Fortune International Company have agreed for Cathay to take over the Berlin-based diagnostics company for €7.52 per share – a premium of almost 50%.

Read more

Bioiberica: A boost to the company

In April, Luis Solera assumes the position of CEO at Barcelona-based biotech Bioiberica. He joins from LIPSA, a leading family business in the oils and fats sector.

Read more

Euronext-listed Argenx plans €68.6m IPO in the US

Belgian-Dutch antibody developer Argenx N.V. seeks to raise US$74.7m in a US IPO. The company, which is already listed on Euronext wants to use the proceeds to push development of its autoimmune and cancer drugs.

Read more

Longevity: Healthy ageing

Italian, Swedish, and German researchers have started recruitment for a systematic investigation into the factors affecting longevity. 
Read more

The SIDUS® technology platform

Originates from the in-depth experience and complete protocol system concerning the manufacture of viral vectors for vaccines or gene therapy.

Read more